Is ELOX or LFCR more profitable?

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Lifecore Biomedical -29.93% N/A -16.16%

Do analysts recommend SIGA or ELOX?

Eloxx Pharmaceuticals has a consensus target price of $38.33, indicating a potential upside of 213.95%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eloxx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media favor ELOX or SLGL?

In the previous week, Sol-Gel Technologies had 11 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 14 mentions for Sol-Gel Technologies and 3 mentions for Eloxx Pharmaceuticals. Sol-Gel Technologies' average media sentiment score of 0.91 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELOX or ACOG?

In the previous week, Alpha Cognition had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 4 mentions for Alpha Cognition and 3 mentions for Eloxx Pharmaceuticals. Alpha Cognition's average media sentiment score of 0.54 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZNTL or ELOX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Eloxx Pharmaceuticals N/A N/A N/A

Does the media refer more to ZNTL or ELOX?

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.89 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eloxx Pharmaceuticals (ELOX) Competitors

$12.21 -0.49 (-3.86%)

As of 10/14/2026 04:00 PM Eastern

Compare

ELOX vs. LFCR, SIGA, SLGL, ACOG, and ZNTL

Should you buy Eloxx Pharmaceuticals stock or one of its competitors? Eloxx Pharmaceuticals's main competitors and comparable companies include Lifecore Biomedical (LFCR), Siga Technologies (SIGA), Sol-Gel Technologies (SLGL), Alpha Cognition (ACOG), and Zentalis Pharmaceuticals (ZNTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eloxx Pharmaceuticals compare to Lifecore Biomedical?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Eloxx Pharmaceuticals has a beta of -1960.42, indicating that its share price is 196,142% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.46 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Lifecore Biomedical	Neutral

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Lifecore Biomedical. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	7.76	-$5.99M	-$1.54	N/A
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Lifecore Biomedical	-29.93%	N/A	-16.16%

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, suggesting a potential upside of 213.95%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 1.25%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats Lifecore Biomedical on 9 of the 15 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.82 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Very Positive
Eloxx Pharmaceuticals	Neutral

Eloxx Pharmaceuticals has a consensus target price of $38.33, indicating a potential upside of 213.95%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Eloxx Pharmaceuticals	N/A	N/A	N/A

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Siga Technologies has higher revenue and earnings than Eloxx Pharmaceuticals. Siga Technologies is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.36	$23.28M	-$0.05	N/A
Eloxx Pharmaceuticals	$6.36M	7.76	-$5.99M	-$1.54	N/A

Siga Technologies has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, indicating that its share price is 196,142% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Siga Technologies on 10 of the 16 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Sol-Gel Technologies?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, suggesting a potential upside of 213.95%. Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 184.17%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eloxx Pharmaceuticals has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	7.76	-$5.99M	-$1.54	N/A
Sol-Gel Technologies	$1.80M	126.76	-$6.13M	-$5.64	N/A

Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

In the previous week, Sol-Gel Technologies had 11 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 14 mentions for Sol-Gel Technologies and 3 mentions for Eloxx Pharmaceuticals. Sol-Gel Technologies' average media sentiment score of 0.91 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Summary

Eloxx Pharmaceuticals beats Sol-Gel Technologies on 9 of the 16 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Alpha Cognition?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Alpha Cognition. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	7.76	-$5.99M	-$1.54	N/A
Alpha Cognition	$10.22M	18.43	-$20.67M	-$1.10	N/A

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alpha Cognition had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 4 mentions for Alpha Cognition and 3 mentions for Eloxx Pharmaceuticals. Alpha Cognition's average media sentiment score of 0.54 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals presently has a consensus target price of $38.33, suggesting a potential upside of 213.95%. Alpha Cognition has a consensus target price of $18.00, suggesting a potential upside of 108.09%. Given Eloxx Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Alpha Cognition	-153.61%	-54.60%	-43.47%

Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Alpha Cognition on 8 of the 15 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.47	-$137.06M	-$1.95	N/A
Eloxx Pharmaceuticals	$6.36M	7.76	-$5.99M	-$1.54	N/A

Zentalis Pharmaceuticals presently has a consensus price target of $7.50, suggesting a potential upside of 223.28%. Eloxx Pharmaceuticals has a consensus price target of $38.33, suggesting a potential upside of 213.95%. Given Zentalis Pharmaceuticals' higher probable upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.89 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eloxx Pharmaceuticals' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Eloxx Pharmaceuticals	N/A	N/A	N/A

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zentalis Pharmaceuticals has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Eloxx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELOX vs. The Competition

Export

Metric	Eloxx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.26M	$12.13B	$7.18B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.60%
P/E Ratio	N/A	631.84	198.77	18.91
Price / Sales	7.76	747.00	565.69	79.10
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	-0.14	9.15	10.51	5.92
Net Income	-$5.99M	$2.82B	$3.50B	$380.90M
7 Day Performance	-17.94%	-4.55%	-4.32%	-4.38%
1 Month Performance	-25.09%	-8.50%	-8.64%	-7.25%
1 Year Performance	N/A	-6.15%	2.05%	-4.95%

Eloxx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELOX Eloxx Pharmaceuticals	4.1805 of 5 stars	$12.21 -3.9%	$38.33 +214.0%	N/A	$51.26M	$6.36M	N/A	7	News Coverage Gap Up
LFCR Lifecore Biomedical	1.0462 of 5 stars	$6.44 -0.2%	$6.50 +0.9%	-1.8%	$244.15M	$128.87M	N/A	382	High Trading Volume
SIGA Siga Technologies	0.3523 of 5 stars	$3.26 -0.9%	N/A	-62.1%	$236.39M	$94.57M	N/A	49	Positive News
SLGL Sol-Gel Technologies	3.6575 of 5 stars	$71.94 -4.9%	$197.50 +174.5%	+74.7%	$212.54M	$19.39M	N/A	28	News Coverage Analyst Forecast Gap Up
ACOG Alpha Cognition	3.6148 of 5 stars	$9.04 +0.7%	$18.00 +99.1%	+23.9%	$195.57M	$10.22M	N/A	71	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELOX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. LFCR, SIGA, SLGL, ACOG, and ZNTL

How does Eloxx Pharmaceuticals compare to Lifecore Biomedical?

Summary

How does Eloxx Pharmaceuticals compare to Siga Technologies?

Summary

How does Eloxx Pharmaceuticals compare to Sol-Gel Technologies?

Summary

How does Eloxx Pharmaceuticals compare to Alpha Cognition?

Summary

How does Eloxx Pharmaceuticals compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. LFCR, SIGA, SLGL, ACOG, and ZNTL

How does Eloxx Pharmaceuticals compare to Lifecore Biomedical?

Which has more volatility & risk, ELOX or LFCR?

Does the media favor ELOX or LFCR?

Which has higher valuation & earnings, ELOX or LFCR?

Is ELOX or LFCR more profitable?

Do analysts prefer ELOX or LFCR?

Do institutionals & insiders have more ownership in ELOX or LFCR?

Summary

How does Eloxx Pharmaceuticals compare to Siga Technologies?

Does the media refer more to SIGA or ELOX?

Do analysts recommend SIGA or ELOX?

Is SIGA or ELOX more profitable?

Do institutionals & insiders believe in SIGA or ELOX?

Which has higher valuation & earnings, SIGA or ELOX?

Which has more volatility and risk, SIGA or ELOX?

Summary

How does Eloxx Pharmaceuticals compare to Sol-Gel Technologies?

Do analysts recommend ELOX or SLGL?

Do insiders & institutionals have more ownership in ELOX or SLGL?

Which has better valuation and earnings, ELOX or SLGL?

Which has more risk & volatility, ELOX or SLGL?

Does the media favor ELOX or SLGL?

Is ELOX or SLGL more profitable?

Summary

How does Eloxx Pharmaceuticals compare to Alpha Cognition?

Which has higher earnings & valuation, ELOX or ACOG?

Do insiders and institutionals have more ownership in ELOX or ACOG?

Does the media favor ELOX or ACOG?

Do analysts recommend ELOX or ACOG?

Is ELOX or ACOG more profitable?

Which has more volatility & risk, ELOX or ACOG?

Summary

How does Eloxx Pharmaceuticals compare to Zentalis Pharmaceuticals?

Which has stronger valuation and earnings, ZNTL or ELOX?

Do analysts rate ZNTL or ELOX?

Does the media refer more to ZNTL or ELOX?

Is ZNTL or ELOX more profitable?

Do institutionals & insiders have more ownership in ZNTL or ELOX?

Which has more risk & volatility, ZNTL or ELOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools